Suppr超能文献

一项关于奥氮平在健康受试者中诱导的5-羟色胺2(5-HT2)和多巴胺D2受体占有率的正电子发射断层扫描(PET)研究。

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.

作者信息

Nyberg S, Farde L, Halldin C

机构信息

Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.

出版信息

Neuropsychopharmacology. 1997 Jan;16(1):1-7. doi: 10.1016/S0893-133X(96)00218-7.

Abstract

Olanzapine is a new antipsychotic drug with affinity for 5-HT2, D2, D1, and muscarinic receptors. Positron emission tomography and the radioligands [11C]raclopride and [11C]NMSP were used to measure D2 and 5-HT2 receptor occupancy in three healthy subjects after 10 mg olanzapine orally. After seven hours D2 receptor occupancy was 63%, 62% and 59%, respectively. After 9.5 hours 5-HT2 receptor occupancy was 74%, 86% and 92%. D2 and 5-HT2 receptor occupancy was comparable to that found in patients continuously treated with clozapine. Clinical efficacy has been demonstrated for olanzapine in the dose range 5 to 15 mg per day. Extrapolation from our present observations after a 10 mg single-dose suggest, that at the lower end of the clinically examined dose range the D2 and 5-HT2 receptor occupancy should be similar to that induced by standard doses of clozapine. Detailed evaluation of the dose-response characteristics of olanzapine and direct clinical comparison to clozapine will thus provide valuable leads to the clarification of atypical antipsychotic action.

摘要

奥氮平是一种新型抗精神病药物,对5-羟色胺2(5-HT2)、多巴胺2(D2)、多巴胺1(D1)和毒蕈碱受体具有亲和力。利用正电子发射断层扫描以及放射性配体[11C]雷氯必利和[11C]N-甲基螺环哌啶酮([11C]NMSP)对3名健康受试者口服10毫克奥氮平后的D2和5-HT2受体占有率进行了测量。7小时后,D2受体占有率分别为63%、62%和59%。9.5小时后,5-HT2受体占有率分别为74%、86%和92%。D2和5-HT2受体占有率与持续使用氯氮平治疗的患者中的情况相当。已证明奥氮平在每日5至15毫克的剂量范围内具有临床疗效。根据我们目前对10毫克单剂量给药后的观察结果推断,在临床检查的剂量范围下限,D2和5-HT2受体占有率应与标准剂量氯氮平诱导的情况相似。因此,对奥氮平剂量反应特征的详细评估以及与氯氮平的直接临床比较将为阐明非典型抗精神病作用提供有价值的线索。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验